Entera Bio Ltd. Current Part of Debt

Current Part of Debt of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Entera Bio Ltd.

Most recent Current Part of Debtof ENTX including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Entera Bio Ltd.


Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.